Gilead May Owe $1 Billion For Truvada Claim
Advocates have discovered that the drugmaker never sought exclusivity for manufacturing Truvada.
August 19 2019 7:32 AM
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Advocates have discovered that the drugmaker never sought exclusivity for manufacturing Truvada.
Gilead made $3 billion off Truvada in 2018, and it's raising the price again.
The gay man, who had been taking the drug daily since January, encountered a drug-resistant strain of the illness.
Nurx makes getting on the HIV prevention medication as easy as "ordering pizza."
A little education and a lot of innuendo.
In a new three-part video series, VICE weighs the pros and cons of the little blue pill, but it sometimes feels more like a commercial than a critical investigation, leaving many questions unanswered.
Michael Lucas says the legendary playwright and warrior needs to stop an outdated condoms-only prevention campaign.
This is a result of talks between Gilead and the federal government.
Though activists are happy, they’re also skeptical of manufacturer Gilead.
Eventually, you may only have to take it once every six months.
Clinton unveils a plan we can all get behind.
Despite taking Truvada, a man was tested positive for HIV. What does it mean for PrEP and its effectiveness?
This is the first documented case of someone contracting HIV while regularly taking Truvada.
The message is meant for men who may be at greater risk of contracting HIV due to sexual and recreational drug behaviors.
Seven senators sent a letter asking the government to look into Gilead’s PrEP profits.
The hyper focus on condoms can run the risk of ignoring an important personal and public health conversation: many people don’t use condoms because they want to feel more pleasure.
Cananda becomes the third nation in the world to approve PrEP as a treatment plan against HIV.
Gay Brits are finding alternative means to obtain their one-a-day HIV prevention pill.
A recent study shows 100% resistance to HIV for participants on PrEP. Michael Lucas responds to the most frequently-repeated misinformation, and asks why there is resistance to this game-changing prevention technique.
Two new studies, one from Britain and one from France, reinforce optimistic view that PrEP is a gamechanger.